A teal immune-cell-like form beside a peptide ribbon and antibody-like shape.

Safety & quality

Immunogenicity

Also found as: immunogenic · immune response · immune reactions

In plain language

The tendency of a therapeutic substance to provoke an immune response against itself. FDA uses this definition for protein therapeutics.[1]

Source check: 2026-10-04 · Editorial method

How the research uses this term

One measurement used in research is anti-drug antibodies. The phase I thymosin β4 study collected blood to assess antibodies to its investigational preparation.[2]

Reading the evidence

An antibody response and its clinical consequences are separate questions. FDA explains that antibodies can alter a therapeutic protein's effects and can also cause complications; the consequences depend on the response and product.[1]

Used in our guides

Continue reading where this term appears.

References

Definitions and explanations are paraphrased. The source locations below identify the supporting passages and methods.

  1. FDA: Immunogenicity of Protein-based TherapeuticsPrimary agency reference · Definition

    Source locations: General Overview.

  2. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteersPrimary research · Human phase I trial · 2021DOI: 10.1111/jcmm.16693

    Source locations: Trial design and Procedure.

    Review status · Pending
    Source packet file

    A_first_in_human_randomized_double_blind_single_and_multiple_dose_phase_34346165_PMC8419156.pdf